These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 1338225)
1. [Prophylaxis of cytomegalovirus infections with ganciclovir in kidney transplant recipients]. Rondeau E; Bourgeon B; Peraldi MN; Lang P; Buisson C; Schulte KM; Weill B; Sraer JD Presse Med; 1992 Dec; 21(41):1979-80. PubMed ID: 1338225 [TBL] [Abstract][Full Text] [Related]
2. Prophylaxis of CMV disease by ganciclovir (DHPG) in seronegative recipients of renal allograft from seropositive donors. Rondeau E; Bourgeon B; Peraldi MN; Lang P; Buisson C; Schulte KM; Weill B; Sraer JD Transpl Int; 1992; 5 Suppl 1():S30-1. PubMed ID: 14621725 [TBL] [Abstract][Full Text] [Related]
3. Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant recipients. Rondeau E; Bourgeon B; Peraldi MN; Lang P; Buisson C; Schulte KM; Weill B; Sraer JD Nephrol Dial Transplant; 1993; 8(9):858-62. PubMed ID: 8255520 [TBL] [Abstract][Full Text] [Related]
4. Historical comparison of prophylactic ganciclovir for gastrointestinal cytomegalovirus infection in kidney transplant recipients. Kim HC; Hwang EA; Park SB; Kim HT; Cho WH Transplant Proc; 2012 Apr; 44(3):710-2. PubMed ID: 22483474 [TBL] [Abstract][Full Text] [Related]
5. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients. Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989 [TBL] [Abstract][Full Text] [Related]
6. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients. Murray BM; Subramaniam S Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220 [TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies. Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495 [TBL] [Abstract][Full Text] [Related]
8. Comparing cytomegalovirus prophylaxis in renal transplantation: single center experience. Varga M; Remport A; Hídvégi M; Péter A; Kóbori L; Telkes G; Fazakas J; Gerlei Z; Sárváry E; Sulyok B; Járay J Transpl Infect Dis; 2005 Jun; 7(2):63-7. PubMed ID: 16150092 [TBL] [Abstract][Full Text] [Related]
9. Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejection. Dickenmann MJ; Kabulbayev K; Steiger J; Cathomas G; Reusser P; Tamm M Clin Microbiol Infect; 2004 Apr; 10(4):337-9. PubMed ID: 15059125 [TBL] [Abstract][Full Text] [Related]
10. A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients. Nafar M; Pezeshki ML; Farrokhi F; Einollahi B; Pour-Reza-Gholi F; Firouzan A; Farhangi S Transplant Proc; 2005 Sep; 37(7):3053-5. PubMed ID: 16213302 [TBL] [Abstract][Full Text] [Related]
11. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354 [TBL] [Abstract][Full Text] [Related]
12. Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients. Israni A; Krok K; Cohen D; Blumberg E; Bloom RD Transplant Proc; 2004 Dec; 36(10):3019-24. PubMed ID: 15686685 [TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation. Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L; Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546 [TBL] [Abstract][Full Text] [Related]
14. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021 [TBL] [Abstract][Full Text] [Related]